Prior treatment toxicities have not resolved to < Grade 2 according to NCI CTCAE Version 4.0 (except clinically insignificant toxicities such as alopecia). 
Subjects receiving any other investigational agents. 
Patients with active tumor lysis syndrome (TLS) either from laboratory or clinical changes. 
Patients with active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma. 
History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab or other agents used in this study. 
Subjects with uncontrolled intercurrent illness . 
HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with Venetoclax. In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated. HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment. 
Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody. 
Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation 
Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing. 
Women who are pregnant or lactating 
Malabsorption syndrome or other condition that precludes enteral route of administration 
Chemotherapy or radiation within 3 weeks of the first scheduled study treatment. 
Less than 2-year disease free from another primary malignancy (other than squamous or basal cell carcinoma of the skin, "in-situ" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels). Patients who have had completed all anti-cancer treatment for another primary malignancy more than 2 years prior to screening are eligible if they are not considered to have a "currently active" malignancy based on having less than a 30% risk of relapse. 
Major surgery, other than diagnostic surgery, within 2 weeks. 
Medical condition requiring chronic use of high dose systemic corticosteroids (i.e., doses of prednisone higher than 10 mg/day or equivalent). Brief (<15 days) treatment with glucocorticoids (prednisone 100 mg by mouth daily, or equivalent) is acceptable. 
Known allergy to both xanthine oxidase inhibitors and rasburicase. 
Use of warfarin is prohibited. Anticoagulation with low-molecular weight heparin (i.e. enoxaparin) or direct thrombin inhibitors is permitted. 
The following concomitant medications are not allowed from 7 days prior to the first dose of study drug and during venetoclax administration: Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to rifampin, carbamazepine. 
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment. 
Concomitant medications that fall into the categories below could potentially lead to adverse reactions and should be considered cautionary. 
Moderate/Weak CYP3A inducers such as efavirenz and oxcarbazepine 
CYP2C8 substrates such as thiazolidinediones (glitazones) and select statins (because of expected inhibition of the metabolism of CYP2C8 substrates) by venetoclax 
CYP2C9 substrates such as tolbutamide (because of expected inhibition of the metabolism of CYP2C9 substrates by venetoclax. It is recommended to exclude CYP2C9 substrates with a narrow therapeutic index such as phenytoin.       
    

NCT03064867_exc_T3
Condition
tumor lysis syndrome (TLS)
NCT03064867_exc_T4
Condition
central nervous system (CNS) disease
NCT03064867_exc_T5
Condition
meningeal lymphoma
NCT03064867_exc_T6
Qualifier
symptomatic
NCT03064867_exc_T7
Condition
CNS parenchymal lymphoma
NCT03064867_exc_T8
Scope
symptomatic meningeal lymphoma or known CNS parenchymal lymphoma
NCT03064867_exc_T9
Condition
allergic reactions
NCT03064867_exc_T10
Qualifier
severe
NCT03064867_exc_T12
Drug
compounds of similar chemical or biologic composition to rituximab
NCT03064867_exc_T11
Drug
compounds of similar chemical or biologic composition to other agents used in this study
NCT03064867_exc_T14
Scope
compounds of similar chemical or biologic composition to rituximab or other agents used in this study
NCT03064867_exc_T16
Condition
HIV-positive
NCT03064867_exc_T17
Procedure
combination antiretroviral therapy
NCT03064867_exc_T23
Measurement
hepatitis B virus (HBV)
NCT03064867_exc_T24
Measurement
hepatitis B surface antigen (HBsAg)
NCT03064867_exc_T25
Measurement
hepatitis C (HCV) antibody
NCT03064867_exc_T26
Value
positive
NCT03064867_exc_T27
Measurement
HCV antibody
NCT03064867_exc_T28
Value
positive
NCT03064867_exc_T29
Measurement
HCV
NCT03064867_exc_T30
Value
negative
NCT03064867_exc_T31
Scope
positive for HCV antibody
NCT03064867_exc_T32
Procedure
polymerase chain reaction (PCR)
NCT03064867_exc_T33
Condition
HBV infection
NCT03064867_exc_T34
Measurement
total hepatitis B core antibody [HBcAb]
NCT03064867_exc_T35
Value
positive
NCT03064867_exc_T36
Measurement
HBsAg
NCT03064867_exc_T37
Value
negative
NCT03064867_exc_T38
Measurement
HBV DNA
NCT03064867_exc_T39
Value
undetectable
NCT03064867_exc_T40
Scope
positive total hepatitis B core antibody [HBcAb] and negative HBsAg
NCT03064867_exc_T43
Person
Women
NCT03064867_exc_T44
Condition
pregnant
NCT03064867_exc_T45
Condition
lactating
NCT03064867_exc_T46
Condition
Malabsorption syndrome
NCT03064867_exc_T47
Condition
condition that precludes enteral route of administration
NCT03064867_exc_T49
Drug
Chemotherapy
NCT03064867_exc_T50
Procedure
radiation
NCT03064867_exc_T51
Temporal
within 3 weeks of the first scheduled study treatment
NCT03064867_exc_T52
Reference_point
the first scheduled study treatment
NCT03064867_exc_T53
Temporal
Less than 2-year
NCT03064867_exc_T54
Condition
disease free
NCT03064867_exc_T55
Condition
primary malignancy
NCT03064867_exc_T56
Qualifier
another
NCT03064867_exc_T57
Condition
squamous or basal cell carcinoma of the skin
NCT03064867_exc_T58
Condition
"in-situ" carcinoma of the cervix
NCT03064867_exc_T59
Condition
"in-situ" carcinoma of the cervix breast
NCT03064867_exc_T60
Condition
superficial bladder carcinoma
NCT03064867_exc_T61
Condition
localized prostate cancer
NCT03064867_exc_T62
Measurement
prostate specific antigen (PSA) levels
NCT03064867_exc_T63
Value
normal
NCT03064867_exc_T64
Scope
squamous or basal cell carcinoma of the skin, "in-situ" carcinoma of the cervix or breast, superficial bladder carcinoma, or previously treated localized prostate cancer with normal prostate specific antigen (PSA) levels
NCT03064867_exc_T65
Procedure
anti-cancer treatment
NCT03064867_exc_T66
Condition
primary malignancy
NCT03064867_exc_T67
Qualifier
another
NCT03064867_exc_T68
Temporal
more than 2 years prior
NCT03064867_exc_T69
Reference_point
screening
NCT03064867_exc_T70
Negation
are eligible
NCT03064867_exc_T71
Procedure
Major surgery
NCT03064867_exc_T72
Procedure
diagnostic surgery
NCT03064867_exc_T73
Temporal
within 2 weeks
NCT03064867_exc_T74
Drug
systemic corticosteroids
NCT03064867_exc_T75
Drug
prednisone
NCT03064867_exc_T76
Multiplier
higher than 10 mg/day
NCT03064867_exc_T77
Multiplier
high dose
NCT03064867_exc_T78
Condition
Medical condition
NCT03064867_exc_T80
Temporal
chronic
NCT03064867_exc_T81
Scope
doses of prednisone higher than 10 mg/day
NCT03064867_exc_T82
Temporal
<15 days
NCT03064867_exc_T83
Drug
glucocorticoids
NCT03064867_exc_T84
Drug
prednisone
NCT03064867_exc_T85
Multiplier
100 mg daily
NCT03064867_exc_T87
Drug
xanthine oxidase inhibitors
NCT03064867_exc_T88
Drug
rasburicase
NCT03064867_exc_T89
Condition
allergy
NCT03064867_exc_T90
Condition
allergy
NCT03064867_exc_T91
Drug
warfarin
NCT03064867_exc_T92
Procedure
Anticoagulation
NCT03064867_exc_T93
Drug
low-molecular weight heparin
NCT03064867_exc_T94
Drug
enoxaparin
NCT03064867_exc_T95
Drug
direct thrombin inhibitors
NCT03064867_exc_T97
Temporal
7 days prior
NCT03064867_exc_T98
Reference_point
first dose of study drug
NCT03064867_exc_T99
Drug
venetoclax
NCT03064867_exc_T100
Procedure
venetoclax administration
NCT03064867_exc_T101
Drug
Strong CYP3A4 inhibitors
NCT03064867_exc_T102
Drug
fluconazole
NCT03064867_exc_T103
Drug
ketoconazole
NCT03064867_exc_T104
Drug
clarithromycin
NCT03064867_exc_T105
Drug
strong CYP3A4 inducers
NCT03064867_exc_T106
Drug
rifampin
NCT03064867_exc_T107
Drug
carbamazepine
NCT03064867_exc_T108
Scope
rifampin, carbamazepine
NCT03064867_exc_T109
Scope
fluconazole, ketoconazole, and clarithromycin
NCT03064867_exc_T110
Scope
7 days prior to the first dose of study drug and during venetoclax administration
NCT03064867_exc_T111
Scope
Strong CYP3A4 inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYP3A4 inducers included but not limited to rifampin, carbamazepine
NCT03064867_exc_T112
Drug
live-virus vaccines
NCT03064867_exc_T113
Temporal
within 28 days prior
NCT03064867_exc_T114
Reference_point
the initiation of study treatment
NCT03064867_exc_T116
Drug
live-virus vaccines
NCT03064867_exc_T117
Temporal
any time during
NCT03064867_exc_T118
Reference_point
study treatment
NCT03064867_exc_T119
Observation
need for
NCT03064867_exc_T122
Drug
Weak CYP3A inducers
NCT03064867_exc_T123
Drug
Moderate CYP3A inducers
NCT03064867_exc_T124
Drug
efavirenz
NCT03064867_exc_T125
Drug
oxcarbazepine
NCT03064867_exc_T126
Scope
Moderate/Weak CYP3A inducers
NCT03064867_exc_T127
Scope
efavirenz and oxcarbazepine
NCT03064867_exc_T128
Drug
CYP2C8 substrates
NCT03064867_exc_T130
Drug
thiazolidinediones
NCT03064867_exc_T131
Drug
glitazones
NCT03064867_exc_T132
Drug
statins
NCT03064867_exc_T133
Qualifier
select
NCT03064867_exc_T134
Drug
CYP2C9 substrates
NCT03064867_exc_T135
Drug
tolbutamide
NCT03064867_exc_T136
Drug
CYP2C9 substrates
NCT03064867_exc_T137
Drug
phenytoin
NCT03064867_exc_T138
Qualifier
narrow therapeutic index
NCT03064867_exc_T19
Negation
other than
NCT03064867_exc_T140
Negation
other than